Nasal spray in the form of a clear, colorless or yellowish liquid with a faint specific odor.
20 ml - glass aerosol cans (1) with a continuous valve and nozzle - cardboard packs.
Immunostimulating drug based on bacterial lysates. IRS 19 enhances specific and non-specific immunity.
When spraying IRS 19, a fine aerosol is formed that covers the nasal mucosa, which leads to the rapid development of a local immune response. Specific protection is due to locally generated antibodies of the class A secretory immunoglobulin type A (IgA), which prevent the fixation and reproduction of infectious agents on the mucosa. Non-specific immunoprotection is manifested in an increase in the phagocytic activity of macrophages, an increase in the lysozyme content.
Adults and children over 3 months of age:
- prevention of chronic diseases of the upper respiratory tract and bronchi;
- treatment of acute and chronic diseases of the upper respiratory tract and bronchi, such as rhinitis, sinusitis, laryngitis, pharyngitis, tonsillitis, tracheitis, bronchitis and others;
- restoration of local immunity after the transferred flu or other viral infections;
- preparation for planned surgical intervention on ENT organs and the postoperative period.
- autoimmune diseases;
- hypersensitivity to the components of the drug.
Pregnancy and lactation
There is insufficient evidence of the potential for teratogenic or toxic effects on the fetus during pregnancy. Therefore, the use of the drug IRS 19 during pregnancy is not recommended.
At the beginning of treatment, reactions such as sneezing and increased discharge from the nose may occur. As a rule, they are of short duration. If these reactions take a severe course, you should reduce the frequency of administration of the drug or cancel it.
At the beginning of treatment, in rare cases, an increase in body temperature of ≥39 ° C is possible. In this case, the drug should be discontinued. However, one should distinguish such a condition from an increase in body temperature, accompanied by malaise, which may be associated with the development of diseases of ENT organs.
In case of clinical symptoms of a bacterial infection, the appropriateness of prescribing systemic antibiotics should be considered.
When prescribing an IRS drug to 19 patients with bronchial asthma, an increase in seizures is possible. In this case, it is recommended to stop treatment and not to take this class of drugs in the future.
Influence on the ability to drive vehicles and control mechanisms
IRS 19 does not affect the psychomotor functions associated with driving vehicles or driving machines and mechanisms.
|bacteria lysates||43.27 ml|
|including Streptococcus pneumoniae type I||1.11 ml|
|Streptococcus pneumoniae type II||1.11 ml|
|Streptococcus pneumoniae type III||1.11 ml|
|Streptococcus pneumoniae type V||1.11 ml|
|Streptococcus pneumoniae type VIII||1.11 ml|
|Streptococcus pneumoniae type XII||1.11 ml|
|Haemophilus influenzae type B||3.33 ml|
|Klebsiella pneumoniae ss pneumoniae||6.66 ml|
|Staphylococcus aureus ss aureus||9.99 ml|
|Acinetobacter calcoaceticus||3.33 ml|
|Moraxella catarrhalis||2.22 ml|
|Neisseria subflava||2.22 ml|
|Neisseria perflava||2.22 ml|
|Streptococcus pyogenes group A||1.66 ml|
|Streptococcus dysgalactiae group C||1.66 ml|
|Enterococcus faecium||0.83 ml|
|Enterococcus faecalis||0.83 ml|
|Streptococcus group G||1.66 mg|
Excipients: glycine - 4.25 g, sodium merthiolate - not more than 1.2 mg, flavoring based on nerol (linalol, alpha-terpineol, geraniol, methylanthranilate, limonene, geranyl acetate, linalyl acetate, diethylene glycol monoethyl ether, pure phenylethyl alcohol) - 12.5 mg - up to 100 ml.
Dosage and administration
The drug is administered intranasally by aerosol administration of 1 dose (1 dose = 1 short press of a spray).
For the purpose of prevention, adults and children from 3 months old are administered 1 dose of the drug in each nostril 2 times / day for 2 weeks (it is recommended to start the course of treatment 2-3 weeks before the expected rise in the incidence).
For the treatment of acute and chronic diseases of the upper respiratory tract and bronchi, children from 3 months to 3 years of age are prescribed 1 dose of the drug in each nostril 2 times / day after preliminary release from the mucous discharge until the symptoms of infection disappear; children over 3 years old and adults - 1 dose of the drug in each nostril from 2 to 5 times / day until the symptoms of infection disappear.
To restore local immunity after the transferred flu and other respiratory viral infections, children and adults are prescribed 1 dose of the drug in each nostril 2 times / day for 2 weeks.
In preparation for the planned surgical intervention and in the postoperative period, adults and children are prescribed 1 dose of the drug in each nostril 2 times / day for 2 weeks (it is recommended to start the course of treatment 1 week before the planned surgical intervention).
Rules for using the drug
For the correct functioning of the aerosol can, put the nozzle on the can, center it and gently, without effort, press it. After that, the device is ready for use.
When injecting the drug, the bottle should be in a strictly upright position, the patient should not throw his head back.
If you tilt the balloon during injection, the propellant will leak out in a few seconds and the device will become unusable.
With regular use of the drug, it is not recommended to remove the nozzle from the bottle.
If the drug is left for a long time without use, a drop of liquid may evaporate and the crystals formed will clog the nozzle outlet. This happens most often when the nozzle is removed and placed in the packag